How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

12,200 results for

Prostate Cancer Staging

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer Full Text available with Trip Pro

compared to other cancer types, which may account for immunotherapeutic resistance. This hypothesis also implies that select types of prostate tumors may be differentially responsive to immune-based strategies and that the clinical stage, pathological grade and underlying genetic landscape may be important criteria in identifying tumors that respond to immune therapies. One strategy is to target oncogenic driver pathways in combination with immunotherapies with the goal of overcoming tumor immunity (...) Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer Immunotherapy is being tested intensively in clinical trials for prostate cancer; it includes immune checkpoint inhibition, prostate specific antigen (PSA) vaccines and dendritic cell-based strategies. Despite increasing evidence for clinical responses, the consensus of multiple trials is that prostate cancers are poorly responsive to immunotherapy. Prostate cancer has a high degree of pathological and genetic heterogeneity

2017 International journal of molecular sciences

162. LncRNA XIST acts as a tumor suppressor in prostate cancer through sponging miR-23a to modulate RKIP expression Full Text available with Trip Pro

LncRNA XIST acts as a tumor suppressor in prostate cancer through sponging miR-23a to modulate RKIP expression Accumulating evidences have indicated that aberrant expression of long non-coding RNAs (LncRNAs) is tightly associated with cancer development. Previous studies have reported that lncRNA XIST regulates tumor malignancies in several cancers. However, the underlying mechanism of XIST in prostate cancer remains unclear. In the current study, we found that XIST was down-regulated (...) in prostate cancer specimens and cell lines. Low expression of XIST was correlated with poor prognosis and advanced tumor stage in prostate cancer patients. In gain and loss of function assays, we confirmed that XIST suppressed cellular proliferation and metastasis in prostate cancer both in vitro and in vivo. Furthermore, we found that XIST negatively regulates the expression of miR-23a and subsequently promotes RKIP expression at post-transcriptional level. Consequently, we investigated the correlation

2017 Oncotarget

163. The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer Full Text available with Trip Pro

The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer Oligometastasis has been proposed as an intermediate stage of cancer spread between localized disease and widespread metastasis. Oligometastatic malignancy is now being diagnosed more frequently as the result of improvements in diagnostic modalities such as functional imaging. The importance of oligometastasis in managing metastatic prostate cancer (...) is that it is possible to treat with a curative aim by metastasis-directed or local therapy in selected patients. Many studies have shown that these aggressive treatments lead to improved survival in other oligometastatic malignancies. However, few studies have shown definitive benefits of metastasis-directed or local therapy in oligometastatic prostate cancer. Review of the available studies suggests that stereotactic radiotherapy (RT) of metastatic lesions in oligorecurrent disease is a feasible and safe modality

2017 Investigative and clinical urology

164. RETRACTED ARTICLE: Liver X receptors constrain tumor development and metastasis dissemination in PTEN-deficient prostate cancer Full Text available with Trip Pro

RETRACTED ARTICLE: Liver X receptors constrain tumor development and metastasis dissemination in PTEN-deficient prostate cancer Advanced prostate cancer (PCa) is a clinical challenge as no curative therapeutic is available. In this context, a better understanding of metastasis and resistance mechanisms in PCa is an important issue. As phosphatase and tensin homolog (PTEN) loss is the most common genetic lesion in such cancer, we investigate human data sets for mechanisms that can constrain (...) cancer evolution in this setting. Here we report a liver X receptor (LXR) signature, which tightly correlates with PTEN loss, in PCa. Accordingly, the LXR pathway is deregulated in prostate carcinomas in Pten-null mice. Genetic ablation of LXRs in Pten-null mice, exacerbates PCa invasiveness and metastatic dissemination, which involves mesenchymal transition and accumulation of matrix metalloproteinases. Mechanistically, PTEN deletion governed LXR transcriptional activity through deregulation

2017 Nature communications

165. MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer Full Text available with Trip Pro

MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer Even though aberrant expression of microRNA (miR)-30d has been reported in prostate cancer (PCa), its associations with cancer progression remain contradictory. The aim of this study was to investigate clinical significance, biological functions and underlying mechanisms of miR-30d deregulation in PCa.Involvement of miR-30d deregulation in malignant phenotypes (...) of PCa was demonstrated by clinical sample evaluation, and in vitro and in vivo experiments. The mechanisms underlying its regulatory effect on tumor angiogenesis were determined.miR-30d over-expression was observed in both PCa cells and clinical specimens. High-miR-30d was distinctly associated with high pre-operative PSA and Gleason score, advanced clinical and pathological stages, positive metastasis and biochemical recurrence (BCR), and reduced overall survival of PCa patients. Through gain

2017 Molecular Cancer

166. Circulating tumor cells capture disease evolution in advanced prostate cancer Full Text available with Trip Pro

, which is associated with progression to small cell cancer, was identified in castrate resistant and CTC samples, but not treatment-naïve disease. This timecourse correlated with the tumor acquiring neuroendocrine features and a change to neuroendocrine-specific therapy.These data support the use of pooled CTCs to facilitate the genetic analysis of late stage prostate cancer. (...) Circulating tumor cells capture disease evolution in advanced prostate cancer Genetic analysis of advanced cancer is limited by availability of representative tissue. Biopsies of prostate cancer metastasized to bone are invasive with low quantity of tumor tissue. The prostate cancer genome is dynamic, however, with temporal heterogeneity requiring repeated evaluation as the disease evolves. Circulating tumor cells (CTCs) offer an alternative, "liquid biopsy", though single CTC sequencing

2017 Journal of translational medicine

167. Amino‐terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer Full Text available with Trip Pro

Amino‐terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer A major cause of cancer death is its metastasis to the vital organs. Few effective therapies are available for metastatic castration-resistant prostate cancer (PCa), and progressive metastatic lesions such as lymph nodes and bones cause mortality. We recently identified AES as a metastasis suppressor for colon cancer. Here, we have studied the roles of AES in PCa progression. We analyzed (...) and MMP9, and accelerated growth, invasion and lymph node metastasis of the mouse prostate tumor. These results suggest that AES plays an important role in controlling tumor growth and metastasis of PCa by regulating both AR and Notch signaling pathways.© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

2017 Cancer science

168. Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer Full Text available with Trip Pro

Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer Prostate cancer (PCa) is the second leading cause of death from cancer in men. The mechanism underlying tumorigenesis and development of PCa is largely unknown. Here, we identified Kinesin family member 14 (KIF14) as a novel candidate oncogene in PCa. We found that KIF14 was overexpressed in multiple PCa cell lines and primary PCa tissues. Knockdown of KIF14 in DU145 (...) and PC3 prostate cancer cells suppressed cell proliferation, induced cell cycle arrest and apoptosis. Transcriptome analysis by RNA-sequencing demonstrated that KIF4 suppression led to transcriptional changes of genes involved in p53 and TGF-beta signaling pathway. In addition, upregulated expression of GADD45A, GADD45B, p21, PIDD and Shisa5, which contribute to growth arrest and apoptosis induction, and downregulated CCNB1 that promotes cell cycle progression were confirmed by quantitative real-time

2017 Oncotarget

169. 68Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer Full Text available with Trip Pro

prior to radical prostatectomy.The study population consisted of 21 patients with prostate cancer who underwent 68Ga-PSMA I&T PET/CT before either open or laparoscopic radical prostatectomy. Intraprostatic tumor extent, extracapsular extension (ECE) and seminal vesicle invasion (SVI) were assessed on the PET/CT scans. Tracer uptake was quantified in terms of standardized uptake values (SUVs). Imaging findings were correlated with final whole-gland histopathology.Of the 21 patients, two had T stage (...) infiltration of an individual prostate lobe, 75.0%, 100.0%, 100.0% and 97.4% for SVI, and 90.0%, 90.9%, 90.0% and 90.9% for ECE, using an angulated contour of the prostate as the criterion. Tumor volume derived from 68Ga-PSMA I&T PET/CT was significantly correlated with preoperative prostate-specific antigen value (rp = 0.75, p < 0.001) and tumor volume on histopathology (rp = 0.45, p = 0.039).68Ga-PSMA I&T PET/CT prior to radical prostatectomy can contribute to presurgical local staging of prostate cancer

2017 Nuclear medicine and molecular imaging

170. miR-30e* is overexpressed in prostate cancer and promotes NF-κB-mediated proliferation and tumor growth Full Text available with Trip Pro

miR-30e* is overexpressed in prostate cancer and promotes NF-κB-mediated proliferation and tumor growth According to the CDC prostate cancer (CaP) has the highest incidence and second highest mortality rate amongst cancers in American men. Constitutive NF-κB activation is a hallmark of CaP and this pathway drives many pro-tumorigenic characteristics of CaP cells, including cell proliferation and survival. An activated NF-κB gene signature is predictive of CaP progression and biochemical (...) of miR-30e* yet the expression and oncological impact of miR-30e* in CaP is unknown. We report that miR-30e* expression is elevated in multiple murine models of CaP and is most pronounced in late stage disease. miR-30e* drives CaP proliferation and tumor growth through inhibition of IκBα, which results in chronic activation of NF-κB. Additionally, we show that inhibition of miR-30e* improves chemotherapeutic control of CaP. Thus, miR-30e* may prove to be a novel clinical target whose inhibition leads

2017 Oncotarget

171. Diagnosis, Staging and Treatment of Patients with Prostate Cancer

in Ireland, 2010-2012 87 Figure 7 Five year net survival: Prostate Cancer in Ireland 88 Figure 8 Economic Literature Review Results 1377 | A National Clinical Guideline | Diagnosis, staging and treatment of patients with prostate cancer Cancer is a major healthcare challenge. Each year in Ireland, approximately 19,000 people are diagnosed with malignant cancer. Cancer is the second leading cause of death in Ireland after diseases of the circulatory system. Deaths from cancer averaged about 8,800 deaths (...) at three levels. (C) 2.4.2.1 For determining tumour extent in prostate core biopsies, when there are multiple foci of prostate cancer in a single core separated by benign intervening stroma, it is suggested that the collapsing method is used (i.e. where intervening benign tissue is excluded from the measurement). (D) 2.4.3.1 For each biopsy site the presence of biopsies positive for carcinoma and the ISUP 2005 Gleason score should be reported. The pathologists should assign a separate Gleason score

2016 National Clinical Guidelines (Ireland)

172. Chronic obstructive pulmonary disease with short-acting inhaled pharmacotherapy increases the risk of prostate cancer: A two-stage database approach. Full Text available with Trip Pro

Chronic obstructive pulmonary disease with short-acting inhaled pharmacotherapy increases the risk of prostate cancer: A two-stage database approach. Patients with chronic obstructive pulmonary disease (COPD) are at a higher risk of many types of cancer. However, specific investigation of the risk of prostate cancer and the influence of COPD pharmacotherapy in patients with COPD is lacking. This study investigated the risk and influence of COPD pharmacotherapy on risk of prostate cancer (...) of smoking, alcohol drinking, and body mass index in the LHID. The hazard ratio (HR) and adjusted HR were estimated. Moreover, the influence of inhaled medications and other related medication on the risk of prostate cancer was analyzed by Cox proportional hazard regression.The COPD cohort comprised 12,774 patients, and the control cohort comprised 38,322 patients (1:3). The incidence of prostate cancer was 633 per 100,000 person-years in the COPD cohort and 361 per 100,000 person-years in the control

2018 PLoS ONE

173. Prostate Cancer?Pretreatment Detection, Surveillance, and Staging

, not of it” [1], the reality is that prostate cancer is second only to lung cancer as a cause of death from malignancy in American men. Specifically, in 2015, an estimated 220,800 American men were diagnosed with prostate cancer and 27,540 died of the disease [2]. In addition to the personal toll of these deaths, the direct economic cost of prostate cancer in the Unites States has been estimated at approximately $10 billion per year [3]. As with other malignancies, the primary goal during baseline evaluation (...) of prostate cancer is disease characterization; that is, establishing disease extent, both local and distant, and aggressiveness. Determination of tumor aggressiveness is ultimately the most important factor, since this drives patient outcome. Several special circumstances make the accurate baseline evaluation of prostate cancer particularly challenging: ? The currently available standard clinical tools used to evaluate prostate cancer, such as digital rectal examination, serum prostate-specific antigen

2016 American College of Radiology

174. Molecular Biomarkers in Localized Prostate Cancer

attained information (ie, PSA, Grade Group, and/or clinical stage). The goal of a biomarker is to achieve any, or ideally all, of the following: estimate the likelihood of a disease characteristic being present or absent, more accurately determine prognosis, or provide the probability of response to a specific treatment. To evaluate the localized prostate cancer biomarker studies to date, ASCO formed an Expert Panel. The potential role of molecular biomarkers in 4 clinical scenarios was addressed (...) and might benefit from refined risk classification. Literature review, analysis, and clinical interpretation. Twenty studies - were obtained (Data Supplement 4). Management decisions in localized prostate cancer are generally centered around the use of prognostic clinical and pathologic factors to assess tumor aggressiveness and natural history. However, the prognostic accuracy of an isolated clinicopathologic variable—Grade Group, clinical stage, and PSA—is limited. Multivariable models, such as NCCN

2020 American Society of Clinical Oncology Guidelines

175. Abiraterone acetate (Zytiga) - for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer

evidence, the output from the PACE process, and application of the appropriate SMC modifiers, the Committee accepted abiraterone for use in NHSScotland. Other data were also assessed but remain confidential.* Additional information: guidelines and protocols The National Institute for Health and Care Excellence (NICE), published ‘Prostate cancer: diagnosis and management’ guideline number 131 in 2019. This guideline stratifies the risk of disease according to PSA levels, Gleason score and clinical stage (...) short form, observed as two consecutive evaluations), the median time was not reached in the abiraterone group compared to 16.6 months in the placebo group (HR 0.69, 95% confidence interval [CI]: 0.58 to 0.83). 4 STAMPEDE is an ongoing open-label, multi-arm, multi-stage phase II/III study that aims to assess varied therapeutic regimens in the management of high risk locally advanced or metastatic hormone- naïve prostate cancer. The primary outcome was overall survival and PFS was assessed

2020 Scottish Medicines Consortium

176. Darolutamide (Nubeqa) - non-metastatic castration resistant prostate cancer (nmCRPC)

bring would be an advantage. 9 ? Darolutamide is taken orally twice daily which is very manageable for patients. No patient expects 'miracles' at this stage of disease. However, treatment that can extend life with a good quality would bring enormous benefits both physiologically and psychologically to patients and their families/carers. Additional information: guidelines and protocols The European Association of Urology published in 2019 an updated version of their ‘Prostate Cancer Guidelines (...) submission darolutamide (Nubeqa®) is accepted for use within NHSScotland. Indication under review: Darolutamide is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. In a phase III study in men with high risk nmCRPC, treatment with darolutamide was superior to placebo for metastasis-free survival. High risk was defined as prostate specific antigen (PSA) doubling time =10 months and PSA =2

2020 Scottish Medicines Consortium

177. Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines

: RA1061-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of radical prostatectomy for early-stage or screen-detected prostate cancer? What is the clinical effectiveness of radiation therapy for early-stage or screen-detected prostate cancer? What are the evidence-based guidelines on the use of radical prostatectomy for prostate cancer? What are the evidence-based guidelines on the use of radiation therapy (...) for prostate cancer? Key Message One health technology assessment, nine systematic reviews (including one systematic review with meta-analysis and one network meta-analysis), and four randomized controlled trials were identified regarding the clinical effectiveness of radical prostatectomy or radiation therapy for early-stage or screen-detected prostate cancer. In addition, ten evidence-based guidelines were identified regarding the use of radical prostatectomy or radiation therapy for prostate cancer

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

178. Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines

is the clinical effectiveness of cryotherapy for early-stage or screen-detected prostate cancer? What are the evidence-based guidelines on the use of cryotherapy for prostate cancer? Key Message Four systematic reviews (including one systematic review with meta-analysis) were identified regarding the clinical effectiveness of cryotherapy for early-stage or screen-detected prostate cancer. In addition, five evidence-based guidelines were identified regarding the use of cryotherapy for prostate cancer. Files (...) Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Last updated: October 3, 2019 Project Number: RA1062-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

179. EANM Guideline/SNMMI Procedure Standard on [18F]Fluciclovine PET/CT for Prostate Cancer Imaging

, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1-amino-3- 18 F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56–63. 6. Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, et al. Prostate cancer-specific PET radiotracers: a review on the clinical utility in recurrent disease. PractRadiatOncol. 2018;8:28–39. 7. Okudaira H, Shikano N, Nishii R, Miyagi T, Yoshimoto M, Kobayashi M, et al. Putative transport (...) imaging in the staging of biochemically recurrent prostate cancer. J Urol. 2017;197:676–83. 24. Schuster DM, Nieh PT, Jani AB, et al. Anti-3-[( 18 )F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. J Urol. 2014;191:1446–53. 25. Nanni C, Zanoni L, Pultrone C, et al. ( 18 )F-FACBC (anti1-amino-3-( 18 )F

2020 Society of Nuclear Medicine and Molecular Imaging

180. Therapies for Clinically Localized Prostate Cancer

-detected and magnetic resonance imaging (MRI)-staged CLPC. We found no evidence on how biomarkers may modify treatment effects. Background and Purpose The American Cancer Society estimates that, in 2020, prostate cancer will be one of the most frequently diagnosed cancers among U.S. men (191,930 new cases) and the second leading cause of cancer death (33,330). 1 In 90 percent of newly diagnosed cancers, the disease is confined to the prostate gland (known as “clinically localized prostate cancer” [CLPC (...) differences may be limited to men age 65 and older or those with intermediate-risk disease. Active monitoring using PSA-based monitoring probably results in little to no difference in all-cause or prostate cancer mortality compared with RP or EBR plus AD over 10 years. Metastases were infrequent, but AM probably results in a small increase compared with RP and EBR+AD. Effects may not vary by patient or tumor risk factors. Harms were lowest with AM compared with RP or EBR plus AD or AS versus photodynamic

2020 Effective Health Care Program (AHRQ)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>